CLEVELAND, Sept. 16 ChanTest, the leading CRO provider ofion channel testing services for drug-discovery and development, will featurethe latest in its expanding line of services in booth 702 at the SafetyPharmacology Society conference September 23-24, in Madison, Wisconsin. NewFDA Critical Path safety profiling tools include the Cardiac, CNS, CVS, andRespiratory System Channel Panels(TM) designed to complement the FDA and ICHS7A and S7B safety guidances. Therapeutic panels include Pain/Inflammationand Epilepsy Channel Panels.
According to Dr. Arthur (Buzz) Brown, ChanTest's founder and CEO, ChanTesthas validated the panels against the "gold standard" manual patch clamp toensure that results from early screens will correlate with GLP studies in INDsubmissions. "Unlike other CROs that have ion channel testing as a smallcomponent of services, ChanTest has built its name and strong reputation overthe years as the experts in ion channels. We work with customers offering acontinuum of discovery and safety services. We don't just provide raw results,we can tell you what the results mean and can often provide recommendations onhow to improve a target's safety profile toward a successful IND submission."
ChanTest will present three posters at the conference:
#44 Cardiac Channel Panel(TM): A Critical Path Tool for UnderstandingCardiac Risk
#48 Incidence and Specificity of Drug-Induced Trafficking Inhibition ofCardiac Ion Channels
#121 hERG vs. APD/QT Results Often Discordant: Fast and AccurateRepolarization Screen a Necessity Early in Development James W. Kramer,
ChanTest scientists were the first to prove hERG as the target for adversecardiac events linked to non-cardiac drugs: Seldane (terfenadine), Propulsid(cisapride), and Nizoral (ketoconazole), and ChanTest pioneered thedevelopment of functional, cell-based ion channel testing as a means topredict cardiac side effects produced by non-cardiac drugs. Such testing isnow a standard component of regulatory submissions prior to the approval ofdrugs for use in humans. ChanTest is committed to innovation, and is leadingthe next major advance in ion channel research and services with a $10 millionprogram to develop the world's most extensive library or catalog of ionchannels. ChanTest's expert electrophysiologists fully validate the ionchannels for interrogation with functional, pharmacological, and biochemicalassays.
The Eighth Annual Safety Pharmacology Society conference and exhibitiontakes place September 22-25, 2008 at the Monona Terrace Community andConvention Center in Madison, Wisconsin.
The preeminent ion channel services company, ChanTest serves its drugdiscovery and development customers with GLP safety and automated screeningassays using its library of ion channel-expressing cell lines -- the mostcomprehensive in the world. Since its inception in 1998, ChanTest has testedmore than 18,000 compounds for more than 250 global pharmaceutical and biotechcompanies -- helping them to achieve their drug safety and discovery goals.ChanTest works in partnership with customers to speed the drug-developmentprocess, save time and money, and ultimately -- to help make better, saferdrugs. Because of ChanTest's seminal role in this field, along with thecompany's uncompromising commitment to quality, ChanTest was named "mosttrusted fee-for-service provider" for ion channel screening in the HTStec IonChannel Trends Survey for two years in a row. ChanTest is based in Cleveland,Ohio. For more information, please visit www.chantest.com.Arthur M. Brown